Yoshimitsu Shimatani1, Hiroyuki Nodera2, Yusuke Osaki1, Chimeglkham Banzrai1, Kazuhiro Takayasu1, Sachiko Endo1, Yoshiko Shibuta3, Ryuji Kaji1. 1. Department of Neurology, Tokushima University, Tokushima, Japan. 2. Department of Neurology, Tokushima University, Tokushima, Japan. Electronic address: hnodera@tokushima-u.ac.jp. 3. Department of Neurology, Tokushima University, Tokushima, Japan; Department of Neurology, National Hospital Organization Takamatsu Medical Center, Takamatsu, Japan.
Abstract
OBJECTIVE: To describe functional changes of axonal ion channels by a metabolic derivative of glucose, methylglyoxal (MGO), and its potential contribution to diabetic neuropathy. METHODS: (1) In wild-type male mice, multiple excitability measurements of sensory nerves were performed at baseline and 1week after serial administration of MGO (50mg/kg). (2) Excitability testing in patients with diabetic neuropathy (N=17) and healthy controls (N=12) were also conducted, and data were interpreted using mathematical modeling. RESULTS: In the animal study, there was a decrease in threshold changes by long hyperpolarization and in superexcitability after administration of MGO. In the preliminary human study, the threshold changes by long hyperpolarizing current were decreased in patients with diabetes. Mathematical modeling showed increased hyperpolarization-activated cation current (Ih) in the MGO-treated mice and in patients with diabetes. CONCLUSION: Ih was upregulated after MGO administration in normal mice. SIGNIFICANCE: MGO is associated with abnormal axonal excitability. Hyperexcitability in diabetic polyneuropathy may, at least in part, be caused by dysfunctional axonal hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. A future study with a large sample size of the diabetic patients would clarify this hypothesis.
OBJECTIVE: To describe functional changes of axonal ion channels by a metabolic derivative of glucose, methylglyoxal (MGO), and its potential contribution to diabetic neuropathy. METHODS: (1) In wild-type male mice, multiple excitability measurements of sensory nerves were performed at baseline and 1week after serial administration of MGO (50mg/kg). (2) Excitability testing in patients with diabetic neuropathy (N=17) and healthy controls (N=12) were also conducted, and data were interpreted using mathematical modeling. RESULTS: In the animal study, there was a decrease in threshold changes by long hyperpolarization and in superexcitability after administration of MGO. In the preliminary human study, the threshold changes by long hyperpolarizing current were decreased in patients with diabetes. Mathematical modeling showed increased hyperpolarization-activated cation current (Ih) in the MGO-treated mice and in patients with diabetes. CONCLUSION: Ih was upregulated after MGO administration in normal mice. SIGNIFICANCE: MGO is associated with abnormal axonal excitability. Hyperexcitability in diabetic polyneuropathy may, at least in part, be caused by dysfunctional axonal hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. A future study with a large sample size of the diabeticpatients would clarify this hypothesis.
Authors: Ryan B Griggs; Duc V M Nguyen; Leonid M Yermakov; Jeneane M Jaber; Jennae N Shelby; Josef K Steinbrunner; John A Miller; Carlos Gonzalez-Islas; Peter Wenner; Keiichiro Susuki Journal: eNeuro Date: 2021-10-06
Authors: Ryan B Griggs; Leonid M Yermakov; Domenica E Drouet; Duc V M Nguyen; Keiichiro Susuki Journal: ASN Neuro Date: 2018 Jan-Dec Impact factor: 4.146
Authors: Parham Azimi; Zahra Keshavarz; Marianne Lahaie Luna; Jose Guillermo Cedeno Laurent; Jose Vallarino; David C Christiani; Joseph G Allen Journal: Int J Environ Res Public Health Date: 2021-01-06 Impact factor: 3.390